DelveInsight’s, “Dengue Pipeline Insight 2026” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Dengue pipeline landscape. It covers the Dengue pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dengue therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Dengue Research @ https://www.delveinsight.com/sample-request/dengue-pipeline-insight

Key Takeaways from the Dengue Pipeline Report

• On June 08, 2026- Hyundai Bioscience Co. Ltd initiated a Phase 2/3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection. In Phase 2, approximately 210 patients with NS1-positive dengue within 72 hours of fever onset will be randomized to receive placebo or CP-COV03 at doses of 450, 900, or 1,350 mg/day for 7 days. An interim analysis by an independent Data and Safety Monitoring Board (DSMB) will support dose selection for Phase 3.
• On May 29, 2026- Takeda conducted a study are to learn about side effects and a participant’s immune response to Takeda’s Dengue Vaccine when given twice within 3 months. Participants will receive 2 doses of their randomized treatment (vaccine or placebo). Children, teenagers and adults will receive one dose of either the vaccine or placebo on Day 1 and the second dose of either the vaccine or placebo 3 months later. Up to 4 blood samples will be taken throughout the study.
• On May 12, 2026- Merck Sharp & Dohme LLC announced a phase 3 study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue serotypes, regardless of dengue serostatus at baseline in children 2 to 17 years of age.
• DelveInsight’s Dengue pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Dengue treatment.
• The leading Dengue Companies such as Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals, and others.
• Promising Dengue Therapies such as EYU688, V181, Butantan-DV, JNJ-64281802, Tetravalent Dengue Vaccine (TDV), and others.

Download for updates and be a part of the revolution in infectious disease care @ Dengue Clinical Trials Assessment

Dengue Overview

Dengue is a mosquito-transmitted virus and the leading cause of arthropod-borne viral disease in the world. It is also known as breakbone fever due to the severity of muscle spasms and joint pain, dandy fever, or seven-day fever because of the usual duration of symptoms. Although most cases are asymptomatic, severe illness and death may occur. Aedes mosquitoes transmit the virus and are common in tropical and subtropical parts of the world. The incidence of dengue has increased dramatically over the past few decades, and the infection is now endemic in some parts of the world.

Dengue Emerging Drugs Profile

• V181: Merck Sharp & Dohme LLC

V181 is an investigational quadrivalent dengue vaccine candidate developed by Merck & Co., aimed at providing immunity against dengue fever, a mosquito-borne viral infection that poses significant health risks worldwide, particularly in tropical and subtropical regions. V181 is designed to be a single-dose vaccination and is being studied in individuals to provide protection against dengue, including severe forms, whether the individuals have been previously infected with the dengue virus or had no prior infections. Early studies suggest that V181 elicits a broad and balanced immune response across all dengue virus types, aiming to provide comprehensive protection and potentially prevent severe outcomes like dengue hemorrhagic fever. Currently the drug is in Phase III stage of its development for the treatment of Dengue.

• ISLA101: Isla Pharmaceuticals

ISLA-101 is the lead antiviral drug candidate being developed by Island Pharmaceuticals for the prevention and treatment of dengue fever and other mosquito-borne viral diseases such as Zika, West Nile, and Yellow Fever. Originally developed for cancer and respiratory conditions, the drug underwent 48 Phase I and II clinical trials and demonstrated a strong safety profile in humans, allowing it to be repurposed for antiviral use. ISLA-101 works by blocking the entry of a key viral protein into the host cell nucleus, thereby preventing viral replication. Preclinical studies conducted by Monash University and Harvard University showed promising antiviral activity against dengue and Zika viruses in animal models. The drug is currently advancing through Phase II clinical trials, with early results indicating favorable safety and potential anti-dengue activity. ISLA-101 is being developed as an oral formulation, with additional exploration into long-acting and intravenous formulations for severe dengue cases.

• EMX-001: Glyden Pharma

EMX-001 is an investigational peptide-based vaccine candidate being developed by Emergex Vaccines for the prevention of dengue and other flaviviral infections, including Zika and yellow fever. It uses a synthetic nanoparticle platform designed to stimulate a strong T-cell immune response rather than relying primarily on antibody production, which may help reduce the risk of antibody-dependent enhancement (ADE) associated with dengue. EMX-001 incorporates dengue-specific peptides delivered through gold nanoparticles and is being explored as a microneedle patch vaccine for easier administration and improved stability. The candidate has completed Phase I clinical evaluation in healthy adults, where it was assessed for safety, tolerability, and immune response generation.

• CDX DENV: Codagenix

CDX-DENV (also referred to as CodaVax-DENV) is an investigational tetravalent live-attenuated dengue vaccine candidate being developed by Codagenix using its proprietary synthetic biology and codon deoptimization platform. The vaccine is designed to provide balanced immunity against all four dengue virus serotypes (DENV-1 to DENV-4), addressing a major challenge in dengue vaccine development where incomplete immunity may increase the risk of antibody-dependent enhancement (ADE). Unlike conventional dengue vaccines based on older viral strains, CDX-DENV is engineered from contemporary circulating dengue strains to improve safety and immune protection. Preclinical studies demonstrated that the vaccine is safe and immunogenic in non-human primates, producing a balanced immune response across all serotypes. The program is currently in the preclinical-to-early clinical development stage, supported by multiple funding awards from the U.S. Department of Defense to advance manufacturing, IND-enabling studies, and Phase I clinical evaluation.

The Dengue Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Dengue with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dengue Treatment.
• Dengue Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dengue Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dengue market

Learn more about Dengue Drugs opportunities in our groundbreaking Dengue Research projects @ Dengue Unmet Needs

Dengue Companies

Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals and others.

Dengue pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Dengue Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Dengue Treatment by visiting our website @ Dengue Market Drivers and Barriers, and Future Perspectives

Scope of the Dengue Pipeline Report

• Coverage- Global
• Dengue Companies- Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals, and others.
• Dengue Therapies- EYU688, V181, Butantan-DV, JNJ-64281802, Tetravalent Dengue Vaccine (TDV), and others.
• Dengue Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Dengue Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Dengue Pipeline on our website @ Dengue Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Dengue: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dengue– DelveInsight’s Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Mid Stage Products (Phase II)
9. Early Stage Products (Phase I)
10. Preclinical and Discovery Stage Products
11. Inactive Products
12. Dengue Key Companies
13. Dengue Key Products
14. Dengue- Unmet Needs
15. Dengue- Market Drivers and Barriers
16. Dengue- Future Perspectives and Conclusion
17. Dengue Analyst Views
18. Dengue Key Companies
19. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/dengue-pipeline-insight